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Summary: The sequence of reactions catalyzed by uricase, catalase and aldehyde dehydrogenase for determination
of the uric acid concentration was evaluated for human serum and urine samples. More than 60 substances were
tested for possible interferences. Alcohol dehydrogenase, formaldehyde and homogentisic acid can disturb the pro-
posed assay, but at concentrations which are not usually encountered in human serum or urine. In the presence of
protein at least 99% of the uric acid was recovered.
Der Nachweis von H^O^bildenden Reaktionen mittels Aldehyddehydrogenase
L Die Bestimmung der Harnsäurekonzentration
Zusammenfassung: Die enzymatische Reaktionsfolge Uricase, Katalase und Aldehyddehydrogenase eignet sich für
die zuverlässige Bestimmung der Harnsäurekonzentration in menschlichen Serum- und Urinproben. Etwa 60 Sub-
stanzen wurden auf eventuelle Interferenzen getestet. Lediglich Alkoholdehydrogenase, Formaldehyd und Homogen-
tisinsäure stören das vorgeschlagene Reaktionsprinzip, allerdings erst in Konzentrationen, mit denen in menschlichen
Serum- und Urinproben nicht zu rechnen ist. In Anwesenheit von Protein werden mindestens 99% der Harnsäure
erfaßt.
Introduction
The uricase reaction is now widely used for the specific
determination of uric acid in biological materials. This
reaction can either be recorded directly at 293 nm or
indicated by various procedures which utilize the H202
produced.
In the method öfKageyama (1), the 2 ?, in the pre-
sence of methanol and catalase, is converted into formal-
dehyde and H2O. The formaldehyde is coupled with ace-
tylaeetone to form 1,3-dihydrplutidine. This procedure
has 2 disadvantages: it proceeds very slowly, even at
37 °C, and the extinction coefficient of the colour
formed is unknown.
Recently, the aldehyde dehydrogenase reaction was pro-
posed as an indicator for the aldehyde formed by the
catalase reaction (2, 3):
ethanol catalas! acetaldehyde + 2 H20H202
acetäldehyde + NAD*
+ NADH + IT
aldehyde
dehydrogenase
The present work evaluates this test principle.
acetate
Materials and Methods
Reagents are purchased from E. Merck AG (D-6100 Darmstadt),
Boehringer-Mannheim (D-6800 Mannheim) or Sigma (St. Louis,
Mo, 63118, USA) as described in table 1. Alcohol: NAD oxido-
reductase, EC 1.1.1.1: Boehringer Mannheim, No. 15320, 2.7 U/
mg (25 °C).
The following solutions are prepared:
L KCl-diphosphate buffer (pH = 8.5):
dilute 3.75 g KC1 (Merck No. 4936) and 22.25 g tetra-sodium-
diphosphate-10-hydrate (Merck No. 6591) in approx. 800 ml
glycerol (260 g/1), adjust pH to 8.5 with HC1 and add glycerol
solution (260 g/1) to 1000 ml.
J. Clin. Chem. Clin. Biochem. / VoL 14,1976 / No. 3
102 Haeckel: Use of aldehyde dehydrogenase to determine H2O2-producing reactions
2. Glycerol(260g/l)
300 g glycerol p. a. (87%, Merck No. 4094) and bidist H2O
to 1000 ml.
3. NAD* or NADF solution.» 10 g/1
100 mg NAD* (Boehringer-Mannheim No. 15300) or 100 mg
NADP+ (Boehringer Mannheim No. 15600) and bidist. H2O
to 10 ml.
4. Catalase, EC 1.1L1.6 (Boehringer Mannheim No. 15674)
5. Ethanol p. a. (Merck No. 972).
6. Aldehyde dehydrogenase,EC 1.2.1.5 (SigmaNo. 121 C-8790).
7. Uricase, EC 1.7.3.3 (Boehringer Mannheim No. 15074).
8. Lithium carbonate: approx. l g Li2CO3 (Merck No. 5671)
and bidist. H2O to 100 ml.
9. Standard solution, 500 /zmol/l uric acid:
840.6 mg uric acid (Merck No. 817), dried overnight under
vacuum, is dissolved in 500 ml bidist. H2O and Li2 C03
solution at 50-80°C. Cool to room temperature; add 1 ml
chloroform (Merck No. 2431) and bidist. H2O to 1000 mL
This solution is stable approx. 4 weeks if stored at 4°C.
Prior to use this solution is diluted 1:10 with bidist. H2O.
10. Reaction mixture (for approx. 100 determinations):
50 ml KQ diphosphate buffer, 5 ml ethanol, 5 ml NAD-
solution, 50 μΐ catalase and 5 mg aldehyde dehydrogenase.
The reaction mixture has to be prepared freshly each day
and was found to be stable for a maximum of 6 hours at
room temperature. The final.concentrations of the assay
mixture are listed in table 1.
Tab. 1. Assay concentrations of reagents used for the determi-
nation of uric acid.
Reaction mixture: pH = 8.5
Na4P207.10 H20 (Merck No.6591) 45 mmol/1
KC1 (Merck No. 4936) 45 mmol/1
NAD* (Boehringer Mannheim No. 15300 1.35 mmol/1
Glycerol (Merck No. 4094) approx. 2.5 mol/1
Ethanol (Merck No. 972) 1.54 mol/1
Catalase (Boehringer Mannheim No. 15674) 900 kU/1
Hydrogen-peroxide: hydrogen peroxide
oxidoreductase (EC 1.11.1.6)
Uricase (Boehringer Mannheim No. 15074) 162 U/l
Urate: oxygen oxidoreductase
(EC 1.7.3.3)
Aldehyde: NAD(P) oxidoreductase 500 U/l
(EC 1.2.1.5) (Reactivated from bakers'
yeast, Sigma No. A 6758)
Sample blank: as above, but without uricase
Sample volume: 50 μΐ
Volume of reaction mixture: 500 μΐ
Wave length: 334 or 340 nm
Reaction temperature: room temperature
For sample blank registration uricase is omitted from the reac-
tion mixture.
Manual assay procedure
extrapolation method using a recorder
Reaction mixture 500 μΐ
(without uricase)
Sample volume (Serum) 50 μΐ
Mix; record absorbance for 1^2 minutes at 334 or 340 nm
(room temperature).
Uricase 5 pi
Mix; record absorbance after reaction has come to an end and
extrapolate to absorbance value before the addition of uricase
(A!)
Uricase 5μ1
Mix and read absorbance difference (A2) immediately.
Calculation: (A! - A2) - 1796 [μηιοΐ/ΐ]
(e ·1 = 6·18
In each series the uricase — absorbance has to be determined just
once. This value can than be used for all samples.
Mechanized procedure
(or for manual measurements in series): sample blank method.






500 μΐ - 500 μΐ -
500 μΐ - 500 μΐ
50 μΐ 50 μΐ -
50 μΐ 50 μΐ
Mix; read absorbance against water or air after 20 minutes (room
temperature).
Calculation: (A3 -* A4) - (Aj - A2) -1780 [μιηοΙ/1]
, NAD(P)H
U 334 nm = 6.18 cm2/μπιοί (4))
For the manual procedure instruments from Eppendorf Ger tebau
GmbH (D-2000 Hamburg) were used: EP 5085 with Philips recor-
der. The mechanized procedure was performed with an Eppendorf
endpoint analyzer 5030 following the instructions of the manu-
facturer. A sample blank was used.
The Kageyama method (1) was performed with a C4 analyzer (9),
the UV-method (293 nm) with a Zeiss P 4 spectrophotometer
using the Boehringer test combination No. 15986 (9). All results
were referred to a standard solution containing 70 g/1 albumin (9).
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Results
Reaction velocity
Under the experimental conditions mentioned above the
amount of uricase was not optimal with respect to the
reaction velocity. The reaction can be speeded up by
adding more uricase (fig. 1). The amount of aldehyde
dehydrogenase chosen did not limit the overall reaction
velocity with the uricase activities used (fig. 2).
Before starting the assay and after the endpoint of the
uricase reaction is reached a slight endogeneous reaction
(A = 0.001-0.002/min) is usually observed. With some
control sera and sera from patients suffering, for instance,
from acute hepatitis, a slight reverse reaction can lead to
slightly erroneous results if neglected. This effect can be
avoided by using NADP* instead of NAD1".
uricose(162U/l)
Fig. 1. The reaction velocity of the test described in table 1 with






18mg/l (162 U/l) uricase
70mg/l (632 U/l) uricase
" 40 -80 ..... 120
Aldehyde dehydrogenose in the reaction mixture
160'
Fig. 2. The influence of the aldehyde dehydrogenase on the
time needed to complete the conversion of uric acid to
acetate by the assay described in table 1.
Precision
All experiments were performed with an Eppendorf end-
point analyzer 5030. The precision data are presented in
table 2. The requirements of the College of American
Pathologists (precision from day to day: CV < 4.6%) and
the Guidelines of the Medical Society of the Federal
Republic of Germany for Statistical Quality Control and
Collaborative Surveys (precision from day to day: CV
< 10%) are satisfied (6, 7).
Accuracy
Under the conditions mentioned above this method is
linear up to a concentration of at least 2000 //mol/1
(fig. 3). Uric acid was added to various serum samples.
The recovery varied from 97.2 to 101.4% (tab. 3). Fur-
thermore for comparison with the Kageyama method
performed with a C4 analyzer from Perkin-Elmer Corp,
the uric acid concentration was measured in unselected
samples from various patients. The correlation between
both procedures was sufficient for clinical purposes
(% 4).
The concentrations of uric acid found in some control
sera were within the range of the values declared by the
manufacturer.
Sensitivity
Sensitivity, understood as detection limit, was not in-
vestigated since the determination of relatively low
uric acid concentrations is unimportant for diagnostic
2000-
500 1000 1500
Uric acid weighed in (mmol/l)
2000
Fig. 3. The relation between different concentrations of uric
acid in aqueous solutions and the amount of uric acid
found by the aldehyde dehydrogenase method. The
standard solutions were prepared with NBS material
dried overnight under vacuum. Analysis of regression:
y = 1.000 χ - 7.671 (n=5), χ = 1050, y = 1051,
r =1.000.
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Tab. 3. Recovery of uric acid added to various sera or aqueous
solutions containing interfering substances. Each value
is a mean of 2 determinations.
Sample Uric acid con- recovery concentration of

















































































ascorbic acid 5 g/1
ascorbic acid 5 g/1
ascorbic acid 5 g/1





homogentisic acid 5 g/1
homogentisic acid 5 g/1
homogentisic acid 5 g/1
homogentisic acid 5 g/1
hqmog. acid 500 mg/1
homog. acid 500 mg/1
homog. acid 500 mg/1
bo„vine albumin 63 g/1
bovine albumin 135 g/1
bovine albumin 63 g/1
bovine albumin 135 g/1
0.0 1000 200.0 300D 400.0 5000 600.0 700jO
Uric acid (Kageyama procedure) [μπιοΐ/ΐ]
Fig. 4. Comparision of the uric acid concentration found in
various human sera with the Kageyama procedure (C4
analyzer) and the aldehyde dehydrogenase method
(Eppendorf endpoint analyzer 5030). Regression ana-
lysis: y =_0.9619 χ + 6.8443, r = 0.967, n = 259, χ = 342
(s=120), y = 336 (s= 119); paired t-test: t = 3.23.
purposes. Some authors report sensitivity in terms of
absorbance signal per concentration (8). A concentra-
tion of 500 μιηοΐ/ΐ uric acid yields an absorbance of
0.27atHg334nm.
Interferences
An extensive study for interference was undertaken as no
results with the aldehyde dehydrogenase reaction in
human sera have been reported so far.
No interference from bilirubin, hemoglobin and ascorbic
acid was found (tab. 3). Samples containing a triglyceride
concentration above 10 mmol/1 should not be analyzed
with the mechanized procedure because of a high blank
absorbance value (approximately 1.0—1.5 at Hg 334 nm).
Further studies were undertaken with a series of drugs as
described in a preceeding report (9). No interference by
these substances was noticed (tab. 4).
During this study we noticed that in the urine from an
alcaptonuric patient less uric acid was found with the
method reported above than was excreted. This effect is
caused by a decomposition of homogentisic acid at pH
8.5 which can be observed at Hg 334 nm (fig. 5).
This pH value was chosen as a compromise between the
pH-optima of all enzymes applied. The interference
from homogentisic acid can be avoided by chosing a
lower pH value. At pH 7.0 the homogentisic acid is
stable, but the NADPH is formed more slowly (fig. 5).
A possible interference from alcohol dehydrogenase
which is released into the blood stream during acute
liver diseases (10,11) was investigated by adding various
amounts of this enzyme to the proposed assay (fig. 6).
In the presence of alcohol dehydrogenase a continuous
increase of absorbance is observed which is accelerated
with the amount of the enzyme added to the reaction
mixture. Under the condition of the proposed assay the
alcohol dehydrogenase reaction does not proceed linear-
fly. Therefore, extrapolation of the absorbance reading to
the start of the aldehyde dehydrogenase reaction (when
uncase is added) leads to a slight overestimation of the
uric acid concentration (approximately + 12% in figure
6). This effect is less pronounced if NADP+ is used in-
stead of NAD+ (fig. 6) and can be avoided with the
sample blank method. However, such high activities of
alcohol dehydrogenase presumably never occur in human
serum (10,11).
Under the proposed assay conditions there was only a
slight production of NADPH in the presence of formal-
dehyde, which caused an absorbance increase of 0.02/
min at Hg 334 run. The resulting higher "endogenous
rate" has no influence on the recovery of uric acid.
An interference of the uric acid determination as sug»
gested above could be expected from inhibitors of the
aldehyde dehydrogenase such as calciumcarbimidum
(calcium cyanamide, trade name: dispan), phenylbuta-
zonum (butazolidin, trade name irgapyrin), disulfirajn
(trade name antabus, no effect up to 1 mmol/1), butyral-
doxim or sulfonylureas (12). the concentrations of
these drugs needed for significant inhibition of the
aldehyde dehydrogenase aire usually not encountered in
human sera.
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Tab. 4. Recovery of uric acid in human pooled seia containing
various drugs. In the absence of any substance added a
mean value of 229 Mmol/l uric acid was found (n = 38,
s = 9.6, 2s -range = 209-245 jumol/1)
Trade name I.N.N.2) concen- uric
tration acid
mg/1 μτηοΐ/ΐ
Glifanan glafeninum 240 213
Aspirin acidum acetylosalicylicum 600 232
Butazolidin phenylbutazonum 120 237
Novalgin novaminsulfonum 800 223
Buscopan hyoscin-N-butylbrominum 12 232
Amuno indometacinum 30 228
Dolviran acidum acetylosalicylicum, 480 234
etc.
Prolixan300 azopropazon-dihydrat 360 223
Actol acidum nilluminicum 150 222
Tanderil oxyphenbutazonum 120 220
Metalcaptase £>-penicillaminum 480 223
Zyloric allopurinolum 80 239
Uricovac benzbromaronum 20 243
Benemid probenecidum 200 230
Lanicor digoxinum 0.15 243
Intensain carbocromenum 90 220
Novadral norfenefrinum 6 219
Miroton glycosides, etc. 6 ml/1 218
Aldaktone spirolactonum 20 232
Sembrina a-methyldopum 320 226
Modenol thiabutazide, etc. 2.6 219
Dipar phenylethylbiguanide 30 234
Euglycon glibenclamidum 3 212
Rastinon tolbutamidum 400 225
Solu-Decortin prednisolonum 200 226
Aponal doxepinum 30 232
Librium chlordiazepoxidum 20 235
Methotrexat acidum methylpteroylgluta- 1 237
minicum
Endoxan cyclophosphamidum 40 227
Megaphen phenothiazinum 30 219
Luminal acidum phenylaethylbar- 80 216
bituricum
Hostacyclin tetracyclinum 200 219
Paraxin chloramphenicolum 600 209
Binotal aminobenzylpeni- 300 225
cillinum
Sulfa- sulfametum 300 225
Furadantin
Furadantin nitrofurantoinum 30 234
Durenat sulfanilamidopyrimidinum 200 237
Refobacin gentamycinum 6 216
Lasix furosemidum 20 216
Dulcolax bisacpdylum 4 229
An io rafui acidum triiodbenzoicum 4itil/l 219
Urografin acidum trijodbenzoicum 4 ml/1 2Ϊ7
Biligraftn adipinyltrijodanilidum 4 ml/1 232
Resochin chloroquinum 100 216
Polybion Vitamine B complex 0.8 ml/1 221
Nicobion nicotinamidum 40 216
Cebion acidum ascorbicum 400 234
Marcumar phenprocoumonum 6 211
Trade name I.N.N.3) concen- uric
tration acid
mg/1 μπιοΐ/ΐ
Macrodex dextranum 6% 100mJ/l 214
Neoplasmagel gelatine 6% 100 ml/1 223





Dura-Clofibrat clofibratum 400 218
Antistin antazolinum 160 217
a) international non-proprietary names as proposed by the
WHO (18).
pHs8.5 pH = 8.5 ___—
L i f s/*™
1 ^/ /
s / § /
v v "~5m '
Fig. 5. The influence of homogen tisic acid on the aldehyde
dehydrogenase method for the determination of the
uric acid concentration,
a: assay condition as indicated in table 1, uric caid
500 μιηοΐ/ΐ;
b: as a, but in the presence of homogentisic acid (5 g/1);
c: as b, but with the reaction mixture at pH 7.O.
j^A334nm = 0.1 ̂  ' ̂ ^^^/
' Ί S ! Γ /^
/ ^ 3/t/ ^
/ 1 7 1 1—5 mm — Ηji j .ji-y }2~~—\
Fig. 6. The influence of alcohol dehydrogenase on the uric acid
determination in the presence of NAD1" (1.1, 2.1 and 3.1)
or NADP* (1.2, 2.2, 3.2 and 3,3). Assay condition:
500 μΐ reaction mixture (table 1) + 50 μΐ uric acid
solution (500 μιηοΐ/ΐ) + 50 μΐ alcohol dehydrogenase
(Boehringer Mannheim, No. 15320) diluted with phos-
phate buffer. The reaction was started by adding 10 μΐ
uricase as indicated by the arrow. The activity of alcohol
dehydrogenase: 1. 4.4 U/l, 2. 22.1 U/l and 3. 44.3 U/l.
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In table 5 the concentration of uric acid determined
with the aldehyde dehydrogenase-, the Kageyama- and
the UV-procedure are reported for some sera containing
high creatinine concentrations.
Urine samples
As reported in a proceeding communication (9) the
Kageyama method can be used to determine the uric
acid concentration in human urine. Therefore, the uric
acid was measured with this procedure and the method
described above. The results from both methods correlate
well (fig. 7). Urine samples were prediluted 1 + 10 with
bidist. wacer.
Discussion
The use of catalase and aldehyde dehydrogenase to
determine the uricase reaction appears to be a suitable
principle for the routine laboratory in clinical chemistry.
In comparison with the UV-method, which measures the
decomposition of uric acid directly a.t 293 nm, it has
the advantages of
— higher sensitivity,
- that it avoids the glycerol effect (13) and
- that it employs the NADH or NADPH band which
can be detected by most photometers used in routine
laboratories.
Tab. 5. The uric acid concentration (μιηοΐ/ΐ) in human sera with
elevated creatinine values determined with the UV - (I),




























































































































0.0 2.0 4.0 6.0 8.0
Uric acid (Kageyama procedure) [jamol/l]
10.0
a) tiiglyceride concentration: 6.6 mmol/1
Fig. 7. The correlation of the uric acid concentration in urine
samples from 29 patients determined with the Kageyama
procedure (9) and the aldehyde dehydrogenase method.
Analysis of regression: y = 1.000 χ - 0.0194, r = 0.9956,
χ = 2.33 (si=1.12), y = 2.31 (s2=1.12); paired t-test:
t = 0.9833.
Comparing the aldehyde dehydrogenase principle with
the Kageyama procedure it is
— much faster and can therefore be recorded at room
temperature,
- it uses NADH or NADPH of which the coefficient of
absorbance il well defined (4), and
- does not lead to an underestimation of the uric acid
concentration in the presence of novaminsulfone.
In a proceeding communication (9) it was shown that
the TJV^method and the Kageyama procedure recovered
only 80-97% of the uric acid concentration from pro-
tein-containing samples. This effect was attributed to
the binding capacity of serum proteins for uric acid,
which in vitro depends on temperature, ionic strength,
pH-value and the concentration of proteins, uric acid or
some drugs (14-17).
It must be assumed that the proportion of uric acid
bound to serum proteins, which is not determined by
the methods mentioned above, varies either in the pre-
sence of specific drugs, or under pathological condi-
tions which may affect the binding capacity. Therefore
new methods for the determination of the uric acid
concentration should avoid this protein related effect.
With the procedure using aldehyde dehydrogenase as
proposed above more than 99% of the uric acid was
recovered, which shows that the binding capacity of
serum proteins is less effective under the conditions used.
Further H202 producing reactions which are of interest
in clinical chemistry are the cholesterol oxidase-, the
glucose oxidase- and the xanthine oxidase reaction,
which can be determined by using the aldehyde de-
hydrogenase principle in the same way as described
above. Reports on these procedures will follow in sepa-
rate communications.
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